•
AN
ANVS
Annovis Bio, Inc.
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
76.33M
Volume
490.55K
52W High
$5.50
52W Low
$1.11
Open
$2.93
Prev Close
$2.88
Day Range
2.93 - 3.19
About Annovis Bio, Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Latest News
Annovis Announces Two Presentations at the CTAD 2025 Conference
GlobeNewswire Inc.•Nov 24
Alzheimer’s Therapeutics Market on Upward Trajectory Across the 7MM During the Forecast Period (2025–2034) Fueled by Drug Development Advances | DelveInsight
GlobeNewswire Inc.•Jul 8
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
GlobeNewswire Inc.•Mar 25
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight
GlobeNewswire Inc.•Mar 3
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
GlobeNewswire Inc.•Feb 13
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.•Feb 7
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
GlobeNewswire Inc.•Feb 5
Annovis Bio, Inc. Announces Proposed Public Offering
GlobeNewswire Inc.•Feb 1